Anti-D Alloimmunization After RhD Positive Red Cell Transfusion to Selected RhD Negative Patients.
Prashant PandeyDivya SetyaMukesh Kumar SinghPublished in: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion (2022)
Transfusion of RhD positive red cells to RhD negative individuals is not routine transfusion practice for the fear of alloimmunization. Aim of this study was to prospectively evaluate rate of alloimmunization after transfusion of RhD positive red cells in RhD negative individuals and to assess delay in transfusion due to decision making. This was a prospective, observational study conducted from 2014 to 2018. All patients were followed up for a period of three months, at 3, 14, 45 and 90 days with antibody screening. In addition, patients who were immunosuppressed and alloimmunized were followed up at 6 months and one year. During the period of the study, there were a total of 57 RhD negative patients (52 males and five females) who received a mean of 4.42 ± 2.85 transfusions. Alloimmunization was detected in 8 (14.03%) patients at a mean interval of 25.63 ± 16.04 days. Anti-D was detected in seven and one patient developed anti-E alloantibody. Mean number of red cell units transfused in alloimmunized was 1.7 ± 0.26 while it was 5.4 ± 1.82 in non-alloimmunized group. There was no delay in providing units to these patients. The TAT was found to be 68 min. Rate of alloimmunization after transfusion of RhD positive red cells to RhD negative individuals was found to be 12.3%. In life saving conditions, RhD negative patients can be transfused RhD positive red cells without delay in decision making.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- sickle cell disease
- prognostic factors
- induced apoptosis
- decision making
- cardiac surgery
- healthcare
- peritoneal dialysis
- primary care
- stem cells
- mesenchymal stem cells
- oxidative stress
- cell therapy
- patient reported outcomes
- cell death
- endoplasmic reticulum stress
- cell cycle arrest